[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356707-105":59,"doc-detail-356707-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","new-pathological-insights-into-biomarkers-for-multimodal-therapeutic-approach-in-hepatic-neuroendocrine-tumors-detailed-case-report","New Pathological Insights into Biomarkers for Multimodal Therapeutic Approach in Hepatic Neuroendocrine Tumors - Detailed Case Report","","Neuroendocrine tumors (NETs) are described as complex and heterogeneous cancers requiring early detection and multimodal therapy, including surgical or locoregional interventions and symptom control such as somatostatin analogs. The article emphasizes the role of biomarkers in diagnosis and treatment, listing established markers like chromogranin A, synaptophysin, Ki-67, somatostatin receptors, mTOR, VEGF/VEGFR, and O6-methylguanine-DNA methyl transferase. A rare 79-year-old case of multifocal primary hepatic NET (WHO grade 2) is presented, using a multimodal strategy after progression on octreotide.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/new-pathological-insights-into-biomarkers-for-multimodal-therapeutic-approach-in-hepatic-neuroendocrine-tumors-detailed-case-report/356707/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/new-pathological-insights-into-biomarkers-for-multimodal-therapeutic-approach-in-hepatic-neuroendocrine-tumors-detailed-case-report/356707.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem is addressed in this case report?","Question",{"text":112,"@type":113},"The report focuses on a rare primary hepatic neuroendocrine tumor with intrahepatic metastases in a 79-year-old male, presenting with epigastric pain and requiring diagnosis and multimodal treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why was a multimodal therapeutic approach chosen?",{"text":117,"@type":113},"Tumor progression occurred under octreotide therapy, and there was a risk of rupture, so combined local and surgical strategies were implemented.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biomarkers are identified as potential novel targets in NET?",{"text":121,"@type":113},"CDK5 and its activator p35 are reported as potential novel biomarkers, with differential expression associated with tumor progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356707,1790386754,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","doi: 10.21873/invivo.14335  \nNew Pathological Insights into Biomarkers for Multimodal Therapeutic Approach in Hepatic Neuroendocrine Tumors: A Detailed Case Report  \nYU-CHIEH TSAI1,2, CHIEN-HUA LIN1,2, CHENG-HSIEN HUNG3,4, JING-JIM OU1,2 and YUEHTSUNG LEE5,6  \n1 Department of Surgery, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.;  \n2 Department of Surgery, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.;  \n3 Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.;  \n4 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.; 5 Department of Post-Baccalaureate Medicine, College of Medicine,  \nNational Chung Hsing University, Taichung, Taiwan, R.O.C.;  \n6 Division of General Surgery, Department of Surgery, Chang-Bing Show Chwan Memorial Hospital, Lukang, Taiwan, R.O.C.  \nAbstract  \nBackground/Aim: Neuroendocrine tumors (NETs) represent a complex, heterogeneous group of cancers with unique characteristics. Early detection and multiple modalities therapies such as surgical intervention or symptom control (e.g., somatostatin analogs) . Treatment for late-stage disease including combining local treatment (surgery, radiofrequency ablation, selective internal radiation therapy, trans-hepatic arterial chemo-embolization/trans-hepatic arterial embolization) with that for systemic disease, such as peptide receptor radionuclide therapy, chemotherapy and targeted therapy, are essential for managing symptoms and improving outcomes. Current biomarkers for neuroendocrine tumors including chromograninA, synaptophysin, Ki-67, somatostatin receptors, mammalian target of rapamycin, vascular endothelial growth factor and its receptor, and O6-methylguanine-DNA methyl transferase are important in diagnosis and treatment of NETs.  \nCase Report: We report a rare case of multifocal primary hepatic neuroendocrine tumor (WHO grade 2) in a 79-yearold male. Due to tumor progression under octreotide therapy and the risk of rupture, a multimodal therapeutic approach was implemented. This included initial transcatheter arterial chemoembolization, followed by left lateral hepatectomy and wedge resection combined with intraoperative radiofrequency ablation. Surgical specimens were analyzed for CDK5 and p35 expression. The patient recovered well without complications and was discharged on postoperative day 9.  \ncontinued  \n✉ Yueh-Tsung Lee, No. 6, Lugong Rd., Lukang Township, Changhua County 50544, Taiwan, R.O.C. E-mail: ytlee89652206@  \n[nchu.edu.tw](nchu.edu.tw), [lee570111@gmail.com](lee570111@gmail.com)  \nReceived January 9, 2026 | Revised February 15, 2026 | Accepted February 24, 2026  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nConclusion: In this case, cyclin-dependent kinase 5 (CDK5) and its activator, p35, were identified as potential novel biomarkers in NET. The differential expression of CDK5 and p35 observed in tumors of varying sizes suggests a correlation with tumor progression. These findings highlight the potential of the CDK5/p35 pathway as a therapeutic target for the management of advanced or metastatic NET.  \nKeywords: Neuroendocrine tumor, metastatic hepatic tumor, CDK5, p35 .  \nIntroduction  \nNeuroendocrine tumors (NETs) represent a complex, heterogeneous group of cancers with unique characteristics. Early detection and multiple modalities therapies such as surgery, trans-hepatic arterial chemoembolization, radiofrequency ablation, somatostatin analogs (octreotide, lanreotide etc.) and peptide receptor radionuclide therapy, are essential for managing symptoms and improving outcomes (1, 2) .  \nHerein, we present the clinical course of a 79-yearold male diagnosed with a rare primary hepatic N","cbCaifdoEThjccwf","https://ap.wps.com/l/cbCaifdoEThjccwf","pdf",1034051,"English","# Abstract\n## Background/Aim\n## Case Report\n# Introduction\n## Clinical course and diagnostic focus\n# Case Presentation\n## Approval and informed consent\n## Initial presentation and diagnostic workup","[{\"question\":\"What clinical problem is addressed in this case report?\",\"answer\":\"The report focuses on a rare primary hepatic neuroendocrine tumor with intrahepatic metastases in a 79-year-old male, presenting with epigastric pain and requiring diagnosis and multimodal treatment.\"},{\"question\":\"Why was a multimodal therapeutic approach chosen?\",\"answer\":\"Tumor progression occurred under octreotide therapy, and there was a risk of rupture, so combined local and surgical strategies were implemented.\"},{\"question\":\"Which biomarkers are identified as potential novel targets in NET?\",\"answer\":\"CDK5 and its activator p35 are reported as potential novel biomarkers, with differential expression associated with tumor progression.\"}]","New Pathological Insights into Biomarkers for Multimodal Therapeutic Approach in Hepatic Neuroendocrine Tumors - Detailed Case Report | PDF",1790126880,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68610e8b0dc3346b60afa8ce26a51f70.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b250c9816e377428250e9adf8935f0c0.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab118cc3da5db4399d23961438835341.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc3f00e51265a607919b4f1ffb479fdd.webp",980,1306]